Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN
Net Margin
Tikun Olam Cannbit Pharmaceuticals Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
IL |
T
|
Tikun Olam Cannbit Pharmaceuticals Ltd
TASE:TKUN
|
32.8m ILS |
-115%
|
|
US |
![]() |
Eli Lilly and Co
NYSE:LLY
|
765.9B USD |
23%
|
|
UK |
![]() |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
US |
![]() |
Johnson & Johnson
NYSE:JNJ
|
399.9B USD |
25%
|
|
DK |
![]() |
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
35%
|
|
CH |
![]() |
Roche Holding AG
SIX:ROG
|
207.3B CHF |
14%
|
|
CH |
![]() |
Novartis AG
SIX:NOVN
|
180.6B CHF |
25%
|
|
UK |
![]() |
AstraZeneca PLC
LSE:AZN
|
167.3B GBP |
14%
|
|
US |
![]() |
Merck & Co Inc
NYSE:MRK
|
211.5B USD |
27%
|
|
IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
US |
![]() |
Pfizer Inc
NYSE:PFE
|
138.2B USD |
13%
|
Tikun Olam Cannbit Pharmaceuticals Ltd
Glance View
Tikun Olam-Cannbit Pharmaceuticals Ltd. engages in the cultivation and marketing of medical cannabis. The firm engages in growing and cultivating medical cannabis products.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Tikun Olam Cannbit Pharmaceuticals Ltd's most recent financial statements, the company has Net Margin of -114.7%.